The tumor/immune interface: Clinical evidence of cancer immunosurveillance, immunoediting and immunosubversion

American Journal of Immunology

Volumn 5, Issue 1, 2009, Pages 29-49

  Block, Matthew S ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

Author keywords

Apoptosis; Cytokines; Immunosuppression; Neoplasm antigens; Regulatory T lymphocytes

Indexed keywords

ANTIRETROVIRUS AGENT; AZATHIOPRINE; B LYMPHOCYTE RECEPTOR; CANCER VACCINE; CELL SURFACE PROTEIN; CHEMOKINE; CYCLOSPORIN; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEOGLYCAN; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TRYPTOPHAN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID METABOLISM; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGENICITY; B LYMPHOCYTE; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER RISK; CANCER SUSCEPTIBILITY; CELL KILLING; COMMON VARIABLE IMMUNODEFICIENCY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPSTEIN BARR VIRUS; GRAFT REJECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSURVEILLANCE; KAPOSI SARCOMA; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; ORGAN TRANSPLANTATION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; REVIEW; SEVERE COMBINED IMMUNODEFICIENCY; SKIN CANCER; T LYMPHOCYTE; TUMOR GROWTH; UTERINE CERVIX CANCER; WART VIRUS; WISKOTT ALDRICH SYNDROME;

EID: 70249099925     PISSN: 1553619X     EISSN: None     Source Type: Journal    
DOI: 10.3844/ajisp.2009.29.49     Document Type: Review

References (188)

1. Coley, W., 1891. Contribution to the knowledge of sarcoma. Ann. Surg., 14: 199-220. http://www.ncbi.nlm.nih.gov/pubmed/17859590
2. Ehrlich, P., 1909. Ueber den jetzigen Stand der Karzinomforschung. Ned. Tijdschr. Geneeskd., 5: 273-290.
3. Burnet, M., 1957. Cancer: A biological approach. I. The processes of control. Br. Med. J., 1: 779-786. http://www.ncbi.nlm.nih.gov/pubmed/ 13404306
4. Thomas, L., 1959. Discussion. In: Cellular and Humoral Aspects of the Hypersensitive States. Lawrence, H.S. (Ed.). Hoeber-Harper, New York, pp: 529-532.
5. Everson, T.C., 1967. Spontaneous regression of cancer. Prog. Clin. Cancer, 3: 79-95.
6. Nathanson, 1976. Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features and possible mechanisms. Natl. Cancer Inst. Monogr., 44: 67-76. http://www.ncbi.nlm.nih.gov/pubmed/799762
7. Herr, H.W. and A. Morales, 2008. History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story. J. Urol., 179: 53-56. http://cat.inist.fr/?aModele=afficheN&cpsidt=20205480
8. O'Day, S.J., O. Hamid and W.J. Urba, 2007. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): A novel strategy for the treatment of melanoma and other malignancies. Cancer, 110: 2614-2627. http://www.ncbi.nlm.nih.gov/pubmed/18000991
9. Philip, M., D.A. Rowley and H. Schreiber, 2004. Inflammation as a tumor promoter in cancer induction. Semin. Cancer Biol., 14: 433-439. http://www.ncbi.nlm.nih.gov/pubmed/15489136
10. Virchow, R., 1863. Aetiologie der Neoplastischen Geschwülste/ Pathogenie der Neoplastischen Geschwülste. In: Die Krankhaften Geschwülste. Verlag von August Hirschwald, Berlin, pp: 57-101.
11. Ribatti, D., M.G. Ennas, A. Vacca, F. Ferreli, B. Nico, S. Orru and P. Sirigu, 2003. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur. J. Clin. Invest., 33: 420-425. http://cat.inist.fr/?aModele=afficheN&cpsidt=1473 5893
12. Leek, R.D., C.E. Lewis, R. Whitehouse, M. Greenall, J. Clarke and A.L. Harris, 1996. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res., 56: 4625-4629. http://www.ncbi.nlm.nih.gov/pubmed/8840975
13. Salvesen, H.B. and L.A. Akslen, 1999. Significance of tumor-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumor angiogenesis and prognosis in endometrial carcinomas. Int. J. Cancer, 84: 538-543. http://cat.inist.fr/ ?aModele=afficheN&cpsidt=1971450
14. Mumm, J.B. and M. Oft, 2008. Cytokine-based transformation of immune surveillance into tumor-promoting inflammation. Oncogene, 27: 5913-5919. http://www.ncbi.nlm.nih.gov/pubmed/18836472
15. Salavoura, K., A. Kolialexi, G. Tsangaris and A. Mavrou, 2008. Development of cancer in patients with primary immunodeficiencies. Anticancer Res., 28: 1263-1269. http://www.ncbi.nlm.nih.gov/pubmed/ 18505064
16. Buell, J.F., T.G. Gross and E.S. Woodle, 2005. Malignancy after transplantation. Transplantation, 80: S254-S264. http://www.ncbi.nlm.nih.gov/pubmed/16251858
17. Chiao, E.Y. and S.E. Krown, 2003. Update on non-acquired immunodeficiency syndrome-defining malignancies. Curr. Opin. Oncol., 15: 389-397. http://www.ncbi.nlm.nih.gov/pubmed/12960522
18. Guba, M., C. Graeb, K.W. Jauch and E.K. Geissler, 2004. Pro-and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation, 77: 1777-1782. http://www.ncbi.nlm.nih.gov/pubmed/15223891
19. Silverberg, M.J. and D.I. Abrams, 2007. AIDS-defining and non-AIDS-defining malignancies: Cancer occurrence in the antiretroviral therapy era. Curr. Opin. Oncol., 19: 446-451. http://www.ncbi.nlm.nih.gov/pubmed/17762569
20. Wong, G. and J.R. Chapman, 2008. Cancers after renal transplantation. Transplant. Rev., 22: 141-149. http://www.journals.elsevierhealth.com/ periodicals/ytrre/article/PIIS0955470X07001310/fulltext
21. Buell, J., T. Gross and T. Beebe et al., 2004. Cancer after Renal Transplantation. In: Cancer and the Kidney, Cohen, E. (Ed.). Oxford University Press, New York City.
22. Buell, J., M. Hanaway and M. Thomas et al., 2004. Malignancies Associated with Liver Transplantation. In: Transplantation of the Liver, Busutill, R. and G. Klintmalm (Eds.). WB Saunders, Philadelphia.
23. Shroff, R. and L. Rees, 2004. The post-transplant lymphoproliferative disorder-a literature review. Pediatr. Nephrol., 19: 369-377. http://www.ncbi.nlm.nih.gov/pubmed/14986084
24. Croul, S., J. Otte and K. Khalili, 2003. Brain tumors and polyomaviruses. J. Neurovirol., 9: 173-182. http://www.ncbi.nlm.nih.gov/ pubmed/12707848
25. Euvrard, S., J. Kanitakis and A. Claudy, 2003. Skin cancers after organ transplantation. N. Engl. J. Med., 348: 1681-1691. http://content.nejm.org/cgi/content/full/348/17/1681
26. Penn, I. and M.E. Brunson, 1988. Cancers after cyclosporine therapy. Transplant. Proc., 20: 885-892. http://www.ncbi.nlm.nih.gov/pubmed/ 3388524
27. Chapman, J. and A. Webster. 2004. Cancer report: ANZDATA Registry 2004 report.
28. Papaconstantinou, H.T., B. Sklow, M.J. Hanaway, T.G. Gross, T.M. Beebe, J. Trofe, R.R. Alloway, E.S. Woodle and J.F. Buell, 2004. Characteristics and survival patterns of solid organ transplant patients developing de novo colon and rectal cancer. Dis. Colon Rectum, 47: 1898-1903. http://www.ncbi.nlm.nih.gov/pubmed/15622583?dopt=Abstract
29. Grulich, A.E., X. Wan, M.G. Law, M. Coates and J.M. Kaldor, 1999. Risk of cancer in people with AIDS. AIDS., 13: 839-843. http://direct.bl.uk/ bld/PlaceOrder.do?UIN=060483620&ETOC=RN&from=searchengine
30. Frisch, M., R.J. Biggar, E.A. Engels, J.J. Goedert and A.I.-C.M.R.S. Group, 2001. Association of cancer with AIDS-related immunosuppression in adults. J. Am. Med. Assoc., 285: 1736-1745. http://www.ncbi.nlm.nih.gov/pubmed/11277828
31. Gallagher, B., Z. Wang, M.J. Schymura, A. Kahn and E.J. Fordyce, 2001. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am. J. Epidemiol., 154: 544-556. http://www.ncbi.nlm.nih.gov/ pubmed/11549560
32. Franceschi, S., L. Dal Maso, S. Arniani, P. Crosignani, M. Vercelli and L. Simonato et al., 1998. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br. J. Cancer, 78: 966-970. http://www.ncbi.nlm.nih.gov/pubmed/9764592
33. Spano, J.P., D. Costagliola, C. Katlama, N. Mounier, E. Oksenhendler and D. Khayat, 2008. AIDS-related malignancies: State of the art and therapeutic challenges. J. Clin. Oncol., 26: 4834-4842. http://www.ncbi.nlm.nih.gov/pubmed/18591544
34. Antoniou, T. and A.L. Tseng, 2005. Interactions between antiretrovirals and antineoplastic drug therapy. Clin. Pharmacokinet., 44: 111-145. http://www.ncbi.nlm.nih.gov/pubmed/15656694
35. Walubo, A., 2007. The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin. Drug Metabol. Toxicol., 3: 583-598. http://d.wanfangdata.com.cn/NSTLQK_NSTL_QK14934914.aspx
36. Sekine, I. and N. Saijo, 2001. Polymorphisms of metabolizing enzymes and transporter proteins involved in the clearance of anticancer agents. Ann. Oncol., 12: 1515-1525. http://www.ncbi.nlm.nih.gov/pubmed/11822749
37. Diamond, C., T.H. Taylor, T. Im and H. Anton-Culver, 2006. Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with Acquired Immunodeficiency Syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk. Lymphoma, 47: 1822-1829. http://www.ncbi.nlm.nih.gov/pubmed/17064995
38. Grulich, A.E., M.T. van Leeuwen, M.O. Falster and C.M. Vajdic, 2007. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet, 370: 59-67. http://www.ncbi.nlm.nih.gov/pubmed/17617273
39. Herman, M., T. Weinstein, A. Korzets, A. Chagnac, Y. Ori, D. Zevin, T. Malachi and U. Gafter, 2001. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J. Lab. Clin. Med., 137: 14-20. http://pt.wkhealth.com/pt/re/jlcm/abstract.0000496 5-200101000-00003.htm;jsessionid=Jr2dh7n2Xgnkndjf4y1Tpyh QTpJN5l92JVjT5WGGHYHzhM7gcd9j!1553038018!181195628!8091!-1
40. Offman, J., G. Opelz, B. Doehler, D. Cummins, O. Halil, N.R. Banner, M.M. Burke, D. Sullivan, P. Macpherson and P. Karran, 2004. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood, 104: 822-828. http://www.ncbi.nlm.nih.gov/pubmed/15090454
41. Andrassy, J., C. Graeb, M. Rentsch, K.W. Jauch and M. Guba, 2005. mTOR inhibition and its effect on cancer in transplantation. Transplantation, 80: 171-174. http://www.ncbi.nlm.nih.gov/pubmed/16286900
42. Hessol, N.A., E.C. Seaberg, S. Preston-Martin, L.S. Massad and H.S. Sacks et al., 2004. Cancer risk among participants in the women's interagency HIV study. J. Acquir. Immune Defic. Syndr., 36: 978-985. http://www.ncbi.nlm.nih.gov/pubmed/15220706
43. Chaturvedi, A.K., R.M. Pfeiffer, L. Chang, J.J. Goedert, R.J. Biggar and E.A. Engels, 2007. Elevated risk of lung cancer among people with AIDS. AIDS., 21: 207-213. http://www.ncbi.nlm.nih.gov/pubmed/17197812
44. Goedert, J.J., C. Schairer, T.S. McNeel, N.A. Hessol, C.S. Rabkin, E.A. Engels and H.A.C.M. Study, 2006. Risk of breast, ovary and uterine corpus cancers among 85, 268 women with AIDS. Br. J. Cancer, 95: 642-648. http://cat.inist.fr/?aModele=afficheN&cpsidt=18102706
45. Prestwich, R.J., F. Errington, P. Hatfield, A.E. Merrick, E.J. Ilett, P.J. Selby and A.A. Melcher, 2008. The immune system-is it relevant to cancer development, progression and treatment? Clin. Oncol. R. Coll. Radiol., 20: 101-112. http://www.ncbi.nlm.nih.gov/pubmed/18037277
46. Swann, J.B. and M.J. Smyth, 2007. Immune surveillance of tumors. J. Clin. Invest., 117: 1137-1146. http://www.jci.org/articles/view/31405
47. Germain, R.N. and D.H. Margulies, 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol., 11: 403-450. http://www.ncbi.nlm.nih.gov/pubmed/8476568
48. Carreno, B.M. and M. Collins, 2002. The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol., 20:29-53. http://www.ncbi.nlm.nih.gov/ pubmed/11861596
49. Watts, T.H., 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol., 23: 23-68. http://www.ncbi.nlm.nih.gov/ pubmed/15771565
50. Shi, Y., J.E. Evans and K.L. Rock, 2003. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature, 425: 516-521. http://www.ncbi.nlm.nih.gov/pubmed/14520412
51. Ohashi, K., V. Burkart, S. Flohe and H. Kolb, 2000. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J. Immunol., 164: 558-561. http://www.ncbi.nlm.nih.gov/pubmed/10623794
52. Asea, A., M. Rehli, E. Kabingu, J.A. Boch, O. Bare, P.E. Auron, M.A. Stevenson and S.K. Calderwood, 2002. Novel signal transduction pathway utilized by extracellular HSP70: Role of Toll-Like Receptor (TLR) 2 and TLR4. J. Biol. Chem., 277: 15028-15034. http://www.ncbi.nlm.nih.gov/ pubmed/11836257
53. Johnson, G.B., G.J. Brunn, Y. Kodaira and J.L. Platt, 2002. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4. J. Immunol., 168: 5233-5239. http://www.ncbi.nlm.nih.gov/pubmed/11994480
54. Termeer, C., F. Benedix, J. Sleeman, C. Fieber, U. Voith and T. Ahrens et al., 2002. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J. Exp. Med., 195: 99-111. http://www.ncbi.nlm.nih.gov/pubmed/11781369
55. Hussein, M.R., 2006. Tumor-associated macrophages and melanoma tumourigenesis: Integrating the complexity. Int. J. Exp. Pathol., 87: 163-176. http://www.ncbi.nlm.nih.gov/pubmed/16709225
56. Smyth, M.J., J. Swann and Y. Hayakawa, 2007. Innate tumor immune surveillance. Adv. Exp. Med. Biol., 590: 103-111. http://www.ncbi.nlm.nih.gov/pubmed/17191380
57. Naama, H.A., V.E. Mack, G.P. Smyth, P.P. Stapleton and J.M. Daly, 2001. Macrophage effector mechanisms in melanoma in an experimental study. Arch. Surg., 136: 804-809. http://www.ncbi.nlm.nih.gov/pubmed/11448395
58. Varney, M.L., K.J. Olsen, R.L. Mosley, C.D. Bucana, J.E. Talmadge and R.K. Singh, 2002. Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: A paracrine role of tumor-associated macrophages in tumor angiogenesis. In Vivo, 16: 471-477. http://www.ncbi.nlm.nih.gov/pubmed/12494891
59. Tan, S.Y., Y. Fan, H.S. Luo, Z.X. Shen, Y. Guo and L.J. Zhao, 2005. Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World J. Gastroenterol., 11: 1210-1214. http://www.ncbi.nlm.nih.gov/pubmed/15754407
60. Alvaro, T., M. Lejeune, M.T. Salvado, C. Lopez, J. Jaen, R. Bosch and L.E. Pons, 2006. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J. Clin. Oncol., 24: 5350-5357. http://www.ncbi.nlm.nih.gov/pubmed/17135637
61. Li, Y., S. Qiu, J. Fan, Q. Gao, J. Zhou, Y. Xiao and Y. Xu et al., 2008. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J. Cancer Res. Clin. Oncol., 135: 439-449. http://www.ncbi.nlm.nih.gov/pubmed/18781326
62. Peng, J., T. Ding, L.M. Zheng and J.Y. Shao, 2006. Influence of tumor-associated macrophages on progression and prognosis of nasopharyngeal carcinoma. Aizheng, 25: 1340-1345. http://www.ncbi.nlm.nih.gov/pubmed/17094898
63. Takayama, H., K. Nishimura, A. Tsujimura, Y. Nakai and K. Aozasa et al., 2009. Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical Bacillus Calmette-Guerin instillation. J. Urol., 181: 1894-1900. http://www.ncbi.nlm.nih.gov/pubmed/19237175
64. Lee, C.H., I. Espinosa, S. Vrijaldenhoven, S. Subramanian and K.D. Montgomery et al., 2008. Prognostic significance of macrophage infiltration in leiomyosarcomas. Clin. Cancer Res., 14: 1423-1430. http://www.ncbi.nlm.nih.gov/pubmed/18316565
65. Chen, J.J., Y.C. Lin, P.L. Yao, A. Yuan and H.Y. Chen et al., 2005. Tumor-associated macrophages: The double-edged sword in cancer progression. J. Clin. Oncol., 23: 953-964. http://www.ncbi.nlm.nih.gov/ pubmed/15598976
66. Herberman, R.B., M.E. Nunn, H.T. Holden and D.H. Lavrin, 1975. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int. J. Cancer, 16: 230-239. http://www.ncbi.nlm.nih.gov/pubmed/1080480
67. Karre, K., H.G. Ljunggren, G. Piontek and R. Kiessling, 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature, 319: 675-678. http://www.ncbi.nlm.nih.gov/ pubmed/3951539
68. Waldhauer, I. and A. Steinle, 2008. NK cells and cancer immunosurveillance. Oncogene, 27: 5932-5943. http://www.ncbi.nlm.nih.gov/ pubmed/18836474
69. Nausch, N. and A. Cerwenka, 2008. NKG2D ligands in tumor immunity. Oncogene, 27: 5944-5958. http://www.ncbi.nlm.nih.gov/pubmed/18836475
70. Bauer, S., V. Groh, J. Wu, A. Steinle, J.H. Phillips, L.L. Lanier and T. Spies, 1999. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science, 285: 727-729. http://www.ncbi.nlm.nih.gov/pubmed/10426993
71. Diefenbach, A., E.R. Jensen, A.M. Jamieson and D.H. Raulet, 2001. Rae1 and H60 ligands of the NKG2D receptor stimulate tumor immunity. Nature, 413: 165-171. http://www.ncbi.nlm.nih.gov/pubmed/11557981
72. Ikeda, H., L.J. Old and R.D. Schreiber, 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev., 13: 95-109. http://www.ncbi.nlm.nih.gov/pubmed/ 11900986
73. Coca, S., J. Perez-Piqueras, D. Martinez, A. Colmenarejo, M.A. Saez, C. Vallejo, J.A. Martos and M. Moreno, 1997. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer, 79: 2320-2328. http://www.ncbi.nlm.nih.gov/pubmed/9191519
74. Ishigami, S., S. Natsugoe, K. Tokuda, A. Nakajo, X. Che, H. Iwashige, K. Aridome, S. Hokita and T. Aikou, 2000. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer, 88: 577-583. http://www.ncbi.nlm.nih.gov/pubmed/10649250
75. Villegas, F.R., S. Coca, V.G. Villarrubia, R. Jimenez and M.J. Chillon et al., 2002. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer, 35: 23-28. http://www.ncbi.nlm.nih.gov/pubmed/ 11750709
76. Porrata, L.F., 2008. Host immunity and survival. Leuk. Lymphoma, 49: 843-844. http://www.ncbi.nlm.nih.gov/pubmed/18464103
77. Ravetch, J.V. and R.A. Clynes, 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol., 16: 421-432. http://www.ncbi.nlm.nih.gov/pubmed/9597136
78. Dropcho, E.J., 2005. Update on paraneoplastic syndromes. Curr. Opin. Neurol., 18: 331-336. http://www.ncbi.nlm.nih.gov/pubmed/15891421
79. Lucchinetti, C.F., D.W. Kimmel and V.A. Lennon, 1998. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology, 50: 652-657. http://www.ncbi.nlm.nih.gov/pubmed/9521251
80. Constant, S.L. and K. Bottomly, 1997. Induction of Th1 and Th2 CD4+ T cell responses: The alternative approaches. Annu. Rev. Immunol., 15: 297-322. http://www.ncbi.nlm.nih.gov/pubmed/9143690
81. Decker, W.K. and E.J. Shpall, 2008. Progress in dendritic cell immunotherapy: Elucidating the enigma of Th-1 polarization. Human Vaccin., 4: 162-164. http://www.ncbi.nlm.nih.gov/pubmed/18382128
82. Cerundolo, V., J.D. Silk, S.H. Masri and M. Salio, 2009. Harnessing invariant NKT cells in vaccination strategies. Nat. Rev. Immunol., 9: 28-38. http://www.ncbi.nlm.nih.gov/pubmed/19079136
83. Maccalli, C., S. Scaramuzza and G. Parmiani, 2009. TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors. Cancer Immunol. Immunother., 58: 801-808. http://www.novoseek.com/ DocumentDetailAction.action?numdocs=0&filters=&corpus= MEDLINE&criterion=1&showType=2&docId=19089424&query= blood
84. Terabe, M. and J.A. Berzofsky, 2008. The role of NKT cells in tumor immunity. Adv. Cancer Res., 101: 277-348. http://www.ncbi.nlm.nih.gov/ pubmed/19055947
85. Beetz, S., L. Marischen, D. Kabelitz and D. Wesch, 2007. Human gamma delta T cells: Candidates for the development of immunotherapeutic strategies. Immunol. Res., 37: 97-111. http://www.ncbi.nlm.nih.gov/ pubmed/17695246
86. Kabelitz, D., D. Wesch and W. He, 2007. Perspectives of gammadelta T cells in tumor immunology. Cancer Res., 67: 5-8. http://www.ncbi.nlm.nih.gov/pubmed/17210676
87. Menard, S., G. Tomasic, P. Casalini, A. Balsari and S. Pilotti et al., 1997. Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin. Cancer Res., 3: 817-819. http://www.ncbi.nlm.nih.gov/pubmed/9815754
88. Funada, Y., T. Noguchi, R. Kikuchi, S. Takeno, Y. Uchida and H.E. Gabbert, 2003. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol. Rep., 10: 309-313. http://www.ncbi.nlm.nih.gov/pubmed/12579264
89. Ruffini, E., S. Asioli, P.L. Filosso, P. Lyberis, M.C. Bruna, L. Macri, L. Daniele and A. Oliaro, 2009. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann. Thorac. Surg., 87: 365-372. http://www.ncbi.nlm.nih.gov/pubmed/19161739
90. Zhang, L., J.R. Conejo-Garcia, D. Katsaros and P.A. Gimotty et al., 2003. Intratumoral T cells, recurrence and survival in epithelial ovarian cancer. N. Engl. J. Med., 348: 203-213. http://www.ncbi.nlm.nih.gov/pubmed/12529460
91. Donskov, F., K.M. Bennedsgaard, H. Von Der Maase, N. Marcussen, R. Fisker, J.J. Jensen, P. Naredi and M. Hokland, 2002. Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: Association to objective response and survival. Br. J. Cancer, 87: 194-201. http://cat.inist.fr/?aModele=afficheN&cpsidt=13843690
92. Clemente, C.G., M.C. Mihm, Jr., R. Bufalino, S. Zurrida, P. Collini and N. Cascinelli, 1996. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77: 1303-1310. http://www.ncbi.nlm.nih.gov/pubmed/8608507
93. Yee, C., J.A. Thompson, P. Roche, D.R. Byrd and P.P. Lee et al., 2000. Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of t cell-mediated vitiligo. J. Exp. Med., 192: 1637-1644. http://www.ncbi.nlm.nih.gov/pubmed/11104805
94. Dudley, M.E., J.R. Wunderlich, J.C. Yang, R.M. Sherry and S.L. Topalian et al., 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol., 23: 2346-2357. http://www.ncbi.nlm.nih.gov/pubmed/15800326
95. Garcia-Lora, A., I. Algarra and F. Garrido, 2003. MHC class I antigens, immune surveillance and tumor immune escape. J. Cell. Physiol., 195: 346-355. http://www.ncbi.nlm.nih.gov/pubmed/12704644
96. Jager, E., M. Ringhoffer, M. Altmannsberger, M. Arand, J. Karbach, D. Jager, F. Oesch and A. Knuth, 1997. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer, 71: 142-147. http://www.ncbi.nlm.nih.gov/pubmed/9139833
97. Khong, H.T., Q.J. Wang and S.A. Rosenberg, 2004. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: Tumor escape by antigen loss and loss of MHC expression. J. Immunother., 27: 184-190. http://www.ncbi.nlm.nih.gov/pubmed/15076135
98. Benitez, R., D. Godelaine, M.A. Lopez-Nevot, F. Brasseur and P. Jimenez et al., 1998. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tiss. Antigens, 52: 520-529. http://www.ncbi.nlm.nih.gov/pubmed/9894850
99. Seliger, B., M.J. Maeurer and S. Ferrone, 2000. Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 21: 455-464. http://www.ncbi.nlm.nih.gov/pubmed/10953098
100. Torres, M.J., F. Ruiz-Cabello, A. Skoudy, G. Berrozpe, P. Jimenez, A. Serrano, F.X. Real and F. Garrido, 1996. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. Tiss. Antigens, 47: 372-381. http://www.ncbi.nlm.nih.gov/pubmed/8795137
101. Sanda, M.G., N.P. Restifo, J.C. Walsh, Y. Kawakami, W.G. Nelson, D.M. Pardoll and J.W. Simons, 1995. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst., 87: 280-285. http://www.ncbi.nlm.nih.gov/pubmed/7707419
102. Serrano, A., C.S. Brady, P. Jimenez, M.F. Duggan-Keen and R. Mendez et al., 2000. A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells. Immunogenetics, 51: 1047-1052. http://www.ncbi.nlm.nih.gov/pubmed/ 11061290
103. Koopman, L.A., W.E. Corver, A.R. Van Der Slik, M.J. Giphart and G.J. Fleuren, 2000. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med., 191: 961-976. http://www.ncbi.nlm.nih.gov/ pubmed/10727458
104. Wang, Z., F.M. Marincola, L. Rivoltini, G. Parmiani and S. Ferrone, 1999. Selective Histocompatibility Leukocyte Antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J. Exp. Med., 190: 205-215. http://www.ncbi.nlm.nih.gov/pubmed/10432284
105. Abril, E., R.E. Mendez, A. Garcia, A. Serrano, T. Cabrera, F. Garrido and F. Ruiz-Cabello, 1996. Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha and gamma-interferon. Tiss. Antigens, 47: 391-398. http://www.ncbi.nlm.nih.gov/pubmed/8795139
106. Groh, V., J. Wu, C. Yee and T. Spies, 2002. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 419: 734-738. http://www.ncbi.nlm.nih.gov/pubmed/12384702
107. Salih, H.R., H.G. Rammensee and A. Steinle, 2002. Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J. Immunol., 169: 4098-4102. http://www.ncbi.nlm.nih.gov/pubmed/12370336
108. Ben-Baruch, A., 2006. The multifaceted roles of chemokines in malignancy. Cancer Metast. Rev., 25: 357-371. DOI: 10.1007/ s10555-006-9003-5
109. Koizumi, K., S. Hojo, T. Akashi, K. Yasumoto and I. Saiki, 2007. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci., 98: 1652-1658. http://www.ncbi.nlm.nih.gov/pubmed/17894551
110. Ueno, T., M. Toi, H. Saji, M. Muta and H. Bando et al., 2000. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis and survival in human breast cancer. Clin. Cancer Res., 6: 3282-3289. http://www.ncbi.nlm.nih.gov/pubmed/10955814
111. Luboshits, G., S. Shina, O. Kaplan, S. Engelberg and D. Nass et al., 1999. Elevated expression of the CC chemokine Regulated on Activation, Normal T cell Expressed and Secreted (RANTES) in advanced breast carcinoma. Cancer Res., 59: 4681-4687. http://www.ncbi.nlm.nih.gov/pubmed/10493525
112. Yang, X., P. Lu, C. Fujii, Y. Nakamoto, J.L. Gao, S. Kaneko, P.M. Murphy and N. Mukaida, 2006. Essential contribution of a chemokine, CCL3 and its receptor, CCR1, to hepatocellular carcinoma progression. Int. J. Cancer, 118: 1869-1876. http://www.ncbi.nlm.nih.gov/pubmed/16284949
113. Hojo, S., K. Koizumi, K. Tsuneyama, Y. Arita and Z. Cui et al., 2007. High-level expression of chemokine CXCL16 by tumor cells correlates with a good prognosis and increased tumor-infiltrating lymphocytes in colorectal cancer. Cancer Res., 67: 4725-4731. http://www.ncbi.nlm.nih.gov/pubmed/17510400
114. Buckanovich, R.J., A. Facciabene, S. Kim, F. Benencia and D. Sasaroli et al., 2008. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med., 14: 28-36. http://www.ncbi.nlm.nih.gov/pubmed/18157142
115. Abrahams, V.M., M. Kamsteeg and G. Mor, 2003. The Fas/Fas ligand system and cancer: Immune privilege and apoptosis. Mol. Biotechnol., 25: 19-30. http://www.ncbi.nlm.nih.gov/pubmed/13679631
116. Rabinovich, G.A., D. Gabrilovich and E.M. Sotomayor, 2007. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol., 25: 267-296. http://www.ncbi.nlm.nih.gov/pubmed/17134371
117. Mouawad, R., D. Khayat and C. Soubrane, 2000. Plasma Fas ligand, an inducer of apoptosis and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res., 10: 461-467. http://www.ncbi.nlm.nih.gov/pubmed/11095407
118. Yu, J. and L. Zhang, 2004. Apoptosis in human cancer cells. Curr. Opin. Oncol., 16: 19-24.
119. Asensio, C., A. Zapata, J. Garcia-Ahijado, B. Gil, P. Salvadores and J. Schneider, 2007. Fas expression is associated with a better prognosis in laryngeal squamous cell carcinoma. Anticancer Res., 27: 4083-4086. http://www.ncbi.nlm.nih.gov/pubmed/18225575
120. Lerma, E., M. Romero, A. Gallardo, C. Pons and J. Munoz et al., 2008. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch., 452: 65-74. DOI: 10.1007/s00428-007-0535-z
121. Leach, D.R., M.F. Krummel and J.P. Allison, 1996. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 271: 1734-1736. http://www.ncbi.nlm.nih.gov/pubmed/8596936
122. Phan, G.Q., J.C. Yang, R.M. Sherry, P. Hwu and S.L. Topalian et al., 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA., 100: 8372-8377. http://www.pnas.org/content/100/14/8372.full.pdf
123. Freeman, G.J., A.J. Long, Y. Iwai, K. Bourque and T. Chernova et al., 2000. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 192: 1027-1034. http://www.ncbi.nlm.nih.gov/ pubmed/11015443
124. Dong, H., S.E. Strome, D.R. Salomao, H. Tamura and F. Hirano et al., 2002. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med., 8: 793-800. http://www.ncbi.nlm.nih.gov/pubmed/12091876
125. Watanabe, N., M. Gavrieli, J.R. Sedy, J. Yang and F. Fallarino et al., 2003. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nature Immunol., 4: 670-679. DOI: 10.1038/ni944
126. Kryczek, I., L. Zou, P. Rodriguez, G. Zhu and S. Wei et al., 2006. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J. Exp. Med., 203: 871-881. http://www.ncbi.nlm.nih.gov/pubmed/16606666
127. Katz, J.B., A.J. Muller and G.C. Prendergast, 2008. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev., 222: 206-221. DOI: 10.1111/j.1600-065X.2008.00610.x
128. Munn, D.H. and A.L. Mellor, 2007. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest., 117: 1147-1154. DOI: 10.1172/ JCI31178
129. Munn, D.H., M. Zhou, J.T. Attwood, I. Bondarev, S.J. Conway, B. Marshall, C. Brown and A.L. Mellor, 1998. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 281: 1191-1193. http://www.ncbi.nlm.nih.gov/pubmed/9712583
130. Brandacher, G., A. Perathoner, R. Ladurner, S. Schneeberger and P. Obrist et al., 2006. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: Effect on tumor-infiltrating T cells. Clin. Cancer Res., 12: 1144-1151. http://www.ncbi.nlm.nih.gov/pubmed/16489067
131. Ino, K., N. Yoshida, H. Kajiyama, K. Shibata and E. Yamamoto et al., 2006. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br. J. Cancer, 95: 1555-1561. http://www.ncbi.nlm.nih.gov/pubmed/17117179
132. Okamoto, A., T. Nikaido, K. Ochiai, S. Takakura and M. Saito et al., 2005. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin. Cancer Res., 11: 6030-6039. http://www.ncbi.nlm.nih.gov/pubmed/ 16115948
133. Munn, D.H., M.D. Sharma, D. Hou, B. Baban and J.R. Lee et al., 2004. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest., 114: 280-290. http://www.ncbi.nlm.nih.gov/pubmed/15254595
134. Ishio, T., S. Goto, K. Tahara, S. Tone, K. Kawano and S. Kitano, 2004. Immunoactivative role of indoleamine 2,3-dioxygenase in human hepatocellular carcinoma. J. Gastroenterol. Hepatol., 19: 319-326. DOI: 10.1111/j.1440-1746.2003.03259.x
135. Camby, I., M. Le Mercier, F. Lefranc and R. Kiss, 2006. Galectin-1: A small protein with major functions. Glycobiology, 16: 137R-157R. http://www.ncbi.nlm.nih.gov/pubmed/16840800
136. Liu, F.T. and G.A. Rabinovich, 2005. Galectins as modulators of tumor progression. Nat. Rev. Cancer, 5: 29-41. http://www.ncbi.nlm.nih.gov/ pubmed/15630413
137. Fukumori, T., Y. Takenaka, T. Yoshii, H.R. Kim, V. Hogan, H. Inohara, S. Kagawa and A. Raz, 2003. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res., 63: 8302-8311. http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd= ShowDetailView&TermToSearch=14678989
138. Perillo, N.L., K.E. Pace, J.J. Seilhamer and L.G. Baum, 1995. Apoptosis of T cells mediated by galectin-1. Nature, 378: 736-739. http://www.ncbi.nlm.nih.gov/pubmed/7501023
139. Sturm, A., M. Lensch, S. Andre, H. Kaltner, B. Wiedenmann, S. Rosewicz, A.U. Dignass and H.J. Gabius, 2004. Human galectin-2: Novel inducer of T cell apoptosis with distinct profile of caspase activation. J. Immunol., 173: 3825-3837. http://www.ncbi.nlm.nih.gov/pubmed/15356130
140. Chung, C.D., V.P. Patel, M. Moran, L.A. Lewis and M.C. Miceli, 2000. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J. Immunol., 165: 3722-3729. http://www.ncbi.nlm.nih.gov/pubmed/11034377
141. Matarrese, P., A. Tinari, E. Mormone, G.A. Bianco, M.A. Toscano, B. Ascione, G.A. Rabinovich and W. Malorni, 2005. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding and fission. J. Biol. Chem., 280: 6969-6985. DOI: 10.1074/jbc.M409752200
142. Zhu, C., A.C. Anderson, A. Schubart, H. Xiong and J. Imitola et al., 2005. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol., 6: 1245-1252. http://www.ncbi.nlm.nih.gov/pubmed/16286920
143. Block, M.S. and S.N. Markovic, 2007. The clinical experience of cancer vaccines for malignant melanoma. G. Ital. Dermatol. Venereol., 142: 149-160. http://direct.bl.uk/bld/PlaceOrder.do?UIN=210242610& ETOC=RN&from=searchengine
144. Markovic, S.N., V.J. Suman, J.N. Ingle, J.S. Kaur and H.C. Pitot et al., 2006. Peptide vaccination of patients with metastatic melanoma: Improved clinical outcome in patients demonstrating effective immunization. Am. J. Clin. Oncol., 29: 352-360. http://www.ncbi.nlm.nih.gov/pubmed/16891861
145. Dix, A.R., W.H. Brooks, T.L. Roszman and L.A. Morford, 1999. Immune defects observed in patients with primary malignant brain tumors. J. Neuroimmunol., 100: 216-232. http://www.ncbi.nlm.nih.gov/pubmed/10695732
146. Melcher, L., 2005. Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy. Clin. Oncol. (R. Coll. Radiol.), 17: 12-15. http://www.ncbi.nlm.nih.gov/pubmed/15714923
147. Rolston, K.V., G.P. Bodey and A. Safdar, 2007. Polymicrobial infection in patients with cancer: An underappreciated and underreported entity. Clin. Infect. Dis., 45: 228-233. http://www.ncbi.nlm.nih.gov/pubmed/ 17578784
148. Vento, S., F. Cainelli and Z. Temesgen, 2008. Lung infections after cancer chemotherapy. Lancet Oncol., 9: 982-992. http://www.ncbi.nlm.nih.gov/pubmed/19071255
149. Kavanaugh, D.Y. and D.P. Carbone, 1996. Immunologic dysfunction in cancer. Hematol. Oncol. Clin. North Am., 10: 927-951. http://www.ncbi.nlm.nih.gov/pubmed/8811309
150. Awwad, M. and R.J. North, 1988. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cell-mediated immunity. J. Exp. Med., 168: 2193-2206. http://jem.rupress.org/cgi/reprint/168/6/2193
151. Yamaguchi, T. and S. Sakaguchi, 2006. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol., 16: 115-123. http://www.ncbi.nlm.nih.gov/pubmed/16376102
152. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh and M. Toda, 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol., 155: 1151-1164. http://www.jimmunol.org/cgi/content/abstract/155/3/1151
153. Dieckmann, D., H. Plottner, S. Berchtold, T. Berger and G. Schuler, 2001. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J. Exp. Med., 193: 1303-1310. http://www.ncbi.nlm.nih.gov/pubmed/11390437
154. Hori, S., T. Nomura and S. Sakaguchi, 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science, 299: 1057-1061. http://www.ncbi.nlm.nih.gov/pubmed/12522256
155. Levings, M.K., R. Sangregorio, C. Sartirana, A.L. Moschin, M. Battaglia, P.C. Orban and M.G. Roncarolo, 2002. Human CD25+CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10 and are distinct from type 1 T regulatory cells. J. Exp. Med., 196: 1335-1346. http://www.ncbi.nlm.nih.gov/pubmed/12438424
156. Baecher-Allan, C. and D.E. Anderson, 2006. Regulatory cells and human cancer. Semin. Cancer Biol., 16: 98-105. DOI: 10.1016/ j.semcancer.2005.11.003
157. Woo, E.Y., C.S. Chu, T.J. Goletz, K. Schlienger and H. Yeh et al., 2001. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res., 61: 4766-4772. http://www.ncbi.nlm.nih.gov/pubmed/11406550
158. Schaefer, C., G.G. Kim, A. Albers, K. Hoermann, E.N. Myers and T.L. Whiteside, 2005. Characteristics of CD4+CD25+ regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer, 92: 913-920. http://www.ncbi.nlm.nih.gov/pubmed/15714205
159. Sasada, T., M. Kimura, Y. Yoshida, M. Kanai and A. Takabayashi, 2003. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer, 98: 1089-1099. http://www.ncbi.nlm.nih.gov/pubmed/ 12942579
160. Liyanage, U.K., T.T. Moore, H.G. Joo, Y. Tanaka and V. Herrmann et al., 2002. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol., 169: 2756-2761. http://www.ncbi.nlm.nih.gov/pubmed/12193750
161. Gray, C.P., P. Arosio and P. Hersey, 2003. Association of increased levels of heavy-chain ferritin with increased CD4+ CD25+ regulatory T-cell levels in patients with melanoma. Clin. Cancer Res., 9: 2551-2559. http://cat.inist.fr/?aModele=afficheN&cpsidt=14995186
162. Curiel, T.J., G. Coukos, L. Zou, X. Alvarez and P. Cheng et al., 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med., 10: 942-949. http://www.ncbi.nlm.nih.gov/pubmed/15322536
163. Ichihara, F., K. Kono, A. Takahashi, H. Kawaida, H. Sugai and H. Fujii, 2003. Increased populations of regulatory T cells in peripheral blood and tumorin-filtrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res., 9: 4404-4408. http://www.ncbi.nlm.nih.gov/pubmed/14555512
164. Almand, B., J.R. Resser, B. Lindman, S. Nadaf and J.I. Clark et al., 2000. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res., 6: 1755-1766. http://www.ncbi.nlm.nih.gov/pubmed/10815894
165. Hoffmann, T.K., J. Muller-Berghaus, R.L. Ferris, J.T. Johnson, W.J. Storkus and T.L. Whiteside, 2002. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res., 8: 1787-1793. http://cat.inist.fr/?aModele=afficheN&cpsidt=13700479
166. Pinzon-Charry, A., C.S. Ho, R. Laherty, T. Maxwell and D. Walker et al., 2005. A population of HLADR+ immature cells accumulates in the blood dendritic cell compartment of patients with different types of cancer. Neoplasia (New York), 7: 1112-1122. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1501170
167. Enk, A.H., H. Jonuleit, J. Saloga and J. Knop, 1997. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer, 73: 309-316. http://www.ncbi.nlm.nih.gov/pubmed/9359474
168. Almand, B., J.I. Clark, E. Nikitina, J. van Beynen and N.R. English et al., 2001. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J. Immunol., 166: 678-689. http://www.ncbi.nlm.nih.gov/pubmed/11123353
169. Danna, E.A., P. Sinha, M. Gilbert, V.K. Clements, B.A. Pulaski and S. Ostrand-Rosenberg, 2004. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res., 64: 2205-2211. http://www.ncbi.nlm.nih.gov/pubmed/ 15026364
170. Schmielau, J. and O.J. Finn, 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res., 61: 4756-4760. http://cancerres.aacrjournals.org/cgi/content/abstract/ 61/12/4756
171. Germano, G., P. Allavena and A. Mantovani, 2008. Cytokines as a key component of cancer-related inflammation. Cytokine, 43: 374-379. http://www.ncbi.nlm.nih.gov/pubmed/18701317
172. Apte, R.N. and E. Voronov, 2008. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy? Immunol. Rev., 222: 222-241. http://www.ncbi.nlm.nih.gov/pubmed/18364005
173. Zidi, I., S. Mestiri, A. Bartegi and N.B. Amor, 2009. TNF-alpha and its inhibitors in cancer. Med. Oncol. http://www.ncbi.nlm.nih.gov/pubmed/ 19277912
174. Rao, V.S., C.E. Dyer, J.K. Jameel, P.J. Drew and J. Greenman, 2006. Potential prognostic and therapeutic roles for cytokines in breast cancer (review). Oncol. Rep., 15: 179-185. http://www.ncbi.nlm.nih.gov/ pubmed/16328053
175. Smith, P.C., A. Hobisch, D.L. Lin, Z. Culig and E.T. Keller, 2001. Interleukin-6 and prostate cancer progression. Cytokine Growth Fact. Rev., 12: 33-40. http://linkinghub.elsevier.com/retrieve/pii/S135961 0100000216
176. Park, S., S. Cheon and D. Cho, 2007. The dual effects of interleukin-18 in tumor progression. Cell. Molecul. Immunol., 4: 329-335. http://www.ncbi.nlm.nih.gov/pubmed/17976312
177. Markovic, S.N., W.K. Nevala, C.B. Uhl, E. Celis and D.J. McKean, 2006. A reproducible method for the enumeration of functional (cytokine producing) versus non-functional peptide-specific cytotoxic T lymphocytes in human peripheral blood. Clin. Exp. Immunol., 145: 438-447. DOI: 10.1111/j.1365-2249.2006.03157.x
178. Shurin, M.R., L. Lu, P. Kalinski, A.M. Stewart-Akers and M.T. Lotze, 1999. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol., 21: 339-359. http://www.ncbi.nlm.nih.gov/pubmed/ 10666777
179. Terabe, M., J.M. Park and J.A. Berzofsky, 2004. Role of IL-13 in regulation of anti-tumor immunity and tumor growth. Cancer Immunol. Immunother., 53: 79-85. http://www.ncbi.nlm.nih.gov/pubmed/14610620
180. Ellyard, J.I., L. Simson and C.R. Parish, 2007. Th2-mediated anti-tumor immunity: Friend or foe? Tiss. Antigens, 70: 1-11. http://www.ncbi.nlm.nih.gov/pubmed/17559575
181. Nevala, W.K., C.M. Vachon, A.A. Leontovich, C.G. Scott, M.A. Thompson and S.N. Markovic, 2009. Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma. Clin. Cancer Res., 15: 1931-1939. http://www.ncbi.nlm.nih.gov/pubmed/19240164
182. Mustea, A., E.I. Braicu, D. Koensgen, S. Yuan, P.M. Sun, F. Stamatian, W. Lichtenegger, F.C. Chen, R. Chekerov and J. Sehouli, 2009. Monitoring of IL-10 in the serum of patients with advanced ovarian cancer: Results from a prospective pilot-study. Cytokine, 45: 8-11. http://www.ncbi.nlm.nih.gov/pubmed/19071030
183. Rautert, R., T. Schinkothe, J. Franklin, M. Weihrauch and B. Boll et al., 2008. Elevated pretreatment interleukin-10 serum level is an International Prognostic Score (IPS)-independent risk factor for early treatment failure in advanced stage Hodgkin lymphoma. Leuk. Lymphoma, 49: 2091-2098. DOI: 10.1080/10428190802441339
184. Li, M.O., Y.Y. Wan, S. Sanjabi, A.K. Robertson and R.A. Flavell, 2006. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol., 24: 99-146. http://www.ncbi.nlm.nih.gov/pubmed/16551245
185. Padua, D. and J. Massague, 2009. Roles of TGFbeta in metastasis. Cell Res., 19: 89-102. DOI: 10.1038/cr.2008.316
186. Toi, M., S. Hoshina, T. Takayanagi and T. Tominaga, 1994. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jap. J. Cancer Res., 85: 1045-1049. http://www.ncbi.nlm.nih.gov/pubmed/7525523
187. Kondo, S., M. Asano, K. Matsuo, I. Ohmori and H. Suzuki, 1994. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochem. Biophys. Acta, 1221: 211-214. http://cat.inist.fr/?aModele=afficheN&cpsidt= 4151792
188. Gabrilovich, D.I., H.L. Chen, K.R. Girgis and H.T. Cunningham et al., 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med., 2: 1096-1103. http://www.ncbi.nlm.nih.gov/pubmed/8837607